Professor, Internal Medicine, University of Utah School of Medicine
Hematology
Dr. Paul J. Shami, MD
|
|
Give Review
Paul Shami practices Hematology. Paul Shami is also published. He has 54 publications published. The lastest publication: "Schedule and concentration-dependent induction of apoptosis in leukemia cells by nitric oxide.' He is registered with Medicare and accepts Medicare payments.
Publications
- Myelodysplastic syndromes, version 2.2015.
- Drug-free macromolecular therapeutics induce apoptosis of patient chronic lymphocytic Leukemia cells.
- REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated Acute myeloid leukaemia.
- Effect of a Pluronic(®) P123 Formulation on the Nitric Oxide-Generating Drug JS-K.
- Acute Myeloid Leukemia, Version 2.2013.
- Cellular distribution studies of the nitric oxide-generating antineoplastic prodrug O(2) -(2,4-dinitrophenyl)1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diola...
- Management of extramedullary leukemia as a presentation of Acute myeloid leukemia.
- Chronic myelogenous Leukemia. Clinical practice guidelines in oncology.
- How to choose frontline therapy for chronic myelogenous Leukemia: so many drugs, not so many patients.
- Activation of the c-Jun N-terminal Kinase/Activating Transcription Factor 3 (ATF3) Pathway Characterizes Effective Arylated Diazeniumdiolate-Based Nitric Oxide-Releasi...
- Acute myeloid leukemia.
- Treatment of Acute lymphoblastic leukemia in adults.
- NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous Leukemia.
- The nitric oxide prodrug JS-K is effective against non-small-Cell lung cancer Cells in vitro and in vivo: involvement of reactive oxygen species.
- NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic syndromes.
- Phase II study of clofarabine monotherapy in previously untreated older adults with Acute myeloid leukemia and unfavorable prognostic factors.
- JS-K, a nitric oxide prodrug, has enhanced cytotoxicity in colon cancer Cells with knockdown of thioredoxin reductase 1.
- 4'-O-methylglycosylation of curcumin by Beauveria bassiana.
- NCCN Task Force: Transfusion and iron overload in patients with Myelodysplastic syndromes.
- Gene expression profiling for nitric oxide prodrug JS-K to kill HL-60 myeloid Leukemia cells.
- JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in h...
- Antitumor activity of JS-K [O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and related O2-aryl diazeniumdiolates in vitro and in ...
- PABA/NO as an antiCancer lead: analogue synthesis, structure revision, solution chemistry, reactivity toward glutathione, and in vitro activity.
- Pancreatic Carcinoma surveillance in patients with familial melanoma.
- Involvement of multiple signaling pathways in follicular Lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy.
- Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory Myeloproliferative disea...
- JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity.
- Angiogenesis in Acute and chronic leukemias.
- Identification and characterization of a novel gene that is upregulated in leukaemia Cells by nitric oxide.
- Who should be screened for hereditary breast Cancer and what should be done with the information?
- Esterase-sensitive nitric oxide donors of the diazeniumdiolate family: in vitro antileukemic activity.
- Malignant carcinoid tumor with myocardial metastases.
- Evidence of increased angiogenesis in patients with Acute myeloid leukemia.
- Schedule and concentration-dependent induction of apoptosis in Leukemia cells by nitric oxide.
- A functional tethered ligand thrombin receptor is present on human hematopoietic progenitor Cells.
- Megaloblastic cytopenia in an AIDS patient treated with trimethoprim-sulfamethoxazole.
- Differential effects of nitric oxide on erythroid and myeloid colony growth from CD34+ human bone marrow Cells.
- A case of retrograde jejunoduodenal intussusception caused by a feeding gastrostomy tube.
- Nitric oxide modulation of the growth and differentiation of freshly isolated Acute non-lymphocytic leukemia cells.
- Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and ...
- Nitric oxide modulation of human Leukemia cell differentiation and gene expression.
- JS-K, a nitric oxide prodrug, induces cytochrome c release and caspase activation in HL-60 myeloid Leukemia cells.
- Acute myeloid leukemia clinical practice guidelines in oncology.
- Chronic myelogenous Leukemia.
- Secondary axillary node Carcinoma following treatment of Hodgkin's disease.
- Gastrointestinal metastases from breast Cancer: a case report.
- JS-K, an arylating nitric oxide (NO) donor, has synergistic anti-leukemic activity with cytarabine (ARA-C).
- Myelodysplastic syndromes.
- Synthesis and in vitro anti-leukemic activity of structural analogues of JS-K, an anti-Cancer lead compound.
- JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple Myeloma model in vivo.
- Evolving treatment strategies for patients newly diagnosed with chronic myeloid Leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy.
- NCCN clinical practice guidelines in oncology: chronic myelogenous Leukemia.
- Synthesis and evaluation of piperazine and homopiperazine analogues of JS-K, an anti-Cancer lead compound.
Schools
American University of Beirut Faculty of Medicine
Duke University Med Center
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- HPC Transplantation (Stem Cell Transplant)
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Basal Cell Carcinoma
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna
- Blue Card PPO
- Cigna HMO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- First Choice Health
- First Health (Coventry Health Care) PPO
- Group Health Cooperative
- Guardian
- HealthFirst
- Humana
- Medicaid
- Medicare MCR
- Molina
- MultiPlan PPO
- PHCS Network PPO
- Options PPO
- United Healthcare
Education
-
Duke University Hospital -
American University of Beirut Faculty of Medicine
Hospital
-
University of Utah Health Care - Hospital and Clinics
Drug Facts
| NPI NUMBER | 1992895510 | |
| NPPES Provider LastName | SHAMI | |
| NPPES Provider FirstName | PAUL | |
| NPPES Provider ZIPCode | 841125500 | |
| NPPES Provider State | UT | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 101.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1992895510 |
| Last Name Of The Provider | SHAMI |
| First Name Of The Provider | PAUL |
| View All |
Similar Doctors
|
|
Dr. Wei Song, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Schickwann Tsai, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott J. Samuelson, MD |
|
|
Dr. Saundra S. Buys, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kelly L. Konopa, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John W. Linford, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ann T. Taylor, MD |
|
|
Dr. Alton H. Wagnon Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Djordje Atanackovic, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hwee Y. Lim, MD |
|
|
Dr. Charles J. Parker, MD
This Doctor is OpenDoctor Recommended.
|